Inflammatory bowel disease in the pregnant woman.
Pregnant women with inflammatory bowel disease and their physicians should be aware of factors that may affect the outcome of the pregnancy. Proper patient education, along with a physician team approach, usually ensure completion of an uneventful pregnancy.
Hanan
I M
IM
University of Chicago Hospitals & Clinics, Illinois 60637, USA.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D001942:Breast Feeding / Q000009:adverse effects; D005260:Female; D005298:Fertility / Q000187:drug effects; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D005817:Genetic Counseling; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000503:physiopathology / Q000628:therapy; D010289:Parenteral Nutrition, Total / Q000009:adverse effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology / Q000628:therapy; D011256:Pregnancy Outcome; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D012460:Sulfasalazine